Use of Cell-free DNA Liquid Biopsy to Predict Glioblastoma Progression
|
By LabMedica International staff writers Posted on 11 Nov 2019 |

Image: A liquid biopsy blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream correlates with how patients will progress after they are diagnosed with glioblastoma (Photo courtesy of University of Pennsylvania School of Medicine).
Cancer researchers have demonstrated the potential clinical utility of liquid biopsy to measure plasma cell-free DNA (cfDNA) in patients with newly diagnosed glioblastoma in order to predict the progression of the disease.
Glioblastoma (GBM) is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of glioblastoma cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Treatment of glioblastoma usually comprises surgical removal of the tumor followed by radiation treatment and chemotherapy using the drug temozolomide (TMZ). These treatments usually fail, mainly due to the presence of a cell subpopulation called glioma stem cells (GSCs), which are resistant to radiation and chemotherapy and capable of self-renewal and tumor generation.
As part of a program to develop methods for predicting the progression of GBM, investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) sought to determine the prognostic impact of plasma cfDNA as well as its role as a surrogate measure of tumor burden and as the subject for next-generation sequencing (NGS).
For this study, the investigators evaluated 42 patients with newly diagnosed GBM. Plasma cfDNA was quantified at baseline prior to initial tumor resection and longitudinally during chemoradiotherapy. Plasma cfDNA was assessed for its association with progression-free survival (PFS) and overall survival (OS), correlated with radiographic tumor burden, and subjected to a targeted NGS panel.
Results revealed that prior to initial surgery, GBM patients had higher plasma cfDNA concentrations than age-matched healthy controls. Plasma cfDNA concentration was correlated with radiographic tumor burden on patients' first post-radiation magnetic resonance imaging scan and tended to rise prior to or concurrently with radiographic tumor progression. Preoperative plasma cfDNA concentration above the mean was associated with inferior PFS. Thus the 28 patients with lowest pre-surgery concentrations of cfDNA - defined as cfDNA that was below the average of the total group - had almost double the length of progression free survival (median 9.5 months) compared with the 14 patients with highest concentrations (median 4.9 months).
Analysis of cfDNA samples from 20 patients by liquid biopsy detected at least one mutation in 11 patients, and all of those mutations differed from those detected in analysis of each patient's solid tumor biopsy.
"Doctors have begun using liquid biopsies more frequently to monitor certain cancers - particularly lung cancer - in recent years as research has shown their effectiveness in other disease sites. But until now, there has been little focus on the clinical utility of liquid biopsy in brain tumors," said senior author Dr. Erica L. Carpenter, assistant professor of medicine at the University of Pennsylvania School of Medicine.
The study was published in the October 30, 2019, online edition of the journal Clinical Cancer Research.
Related Links:
University of Pennsylvania School of Medicine
Glioblastoma (GBM) is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of glioblastoma cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Treatment of glioblastoma usually comprises surgical removal of the tumor followed by radiation treatment and chemotherapy using the drug temozolomide (TMZ). These treatments usually fail, mainly due to the presence of a cell subpopulation called glioma stem cells (GSCs), which are resistant to radiation and chemotherapy and capable of self-renewal and tumor generation.
As part of a program to develop methods for predicting the progression of GBM, investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) sought to determine the prognostic impact of plasma cfDNA as well as its role as a surrogate measure of tumor burden and as the subject for next-generation sequencing (NGS).
For this study, the investigators evaluated 42 patients with newly diagnosed GBM. Plasma cfDNA was quantified at baseline prior to initial tumor resection and longitudinally during chemoradiotherapy. Plasma cfDNA was assessed for its association with progression-free survival (PFS) and overall survival (OS), correlated with radiographic tumor burden, and subjected to a targeted NGS panel.
Results revealed that prior to initial surgery, GBM patients had higher plasma cfDNA concentrations than age-matched healthy controls. Plasma cfDNA concentration was correlated with radiographic tumor burden on patients' first post-radiation magnetic resonance imaging scan and tended to rise prior to or concurrently with radiographic tumor progression. Preoperative plasma cfDNA concentration above the mean was associated with inferior PFS. Thus the 28 patients with lowest pre-surgery concentrations of cfDNA - defined as cfDNA that was below the average of the total group - had almost double the length of progression free survival (median 9.5 months) compared with the 14 patients with highest concentrations (median 4.9 months).
Analysis of cfDNA samples from 20 patients by liquid biopsy detected at least one mutation in 11 patients, and all of those mutations differed from those detected in analysis of each patient's solid tumor biopsy.
"Doctors have begun using liquid biopsies more frequently to monitor certain cancers - particularly lung cancer - in recent years as research has shown their effectiveness in other disease sites. But until now, there has been little focus on the clinical utility of liquid biopsy in brain tumors," said senior author Dr. Erica L. Carpenter, assistant professor of medicine at the University of Pennsylvania School of Medicine.
The study was published in the October 30, 2019, online edition of the journal Clinical Cancer Research.
Related Links:
University of Pennsylvania School of Medicine
Latest Molecular Diagnostics News
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







